Bicycle Therapeutics Limited BCYC 深 滬
已收盤 08-07 16:00:00 美东时间
4.17
+0.200
+5.04%
華盛通- 最 高4.206
- 今 開4.07
- 成交量 28.87万股
- 最 低 4.04
- 昨 收 3.97
- 總市值 2.92亿
- 52周最高 9.1592
- 市盈率 靜 --
- 換手率 0.41%
- 52周最低 3.745
- 委 比 58.90%
- 總股本 6999.29万
- 歷史最高 62.075
- 量 比 1.05
- 振 幅 4.18%
- 歷史最低 3.745
- 每 手 1
- 風險率 1.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $15 to $14.
07-31 03:15
Bicycle Therapeutics Q2 EPS $(0.72) Misses $(0.59) Estimate, Sales $629.000K Miss $4.221M Estimate
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.59) by 22.03 percent. This is a 36.84 percent increase over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $629.00...
07-30 19:56
Bicycle Therapeutics' Zelenectide Pevedotin Plus Pembrolizumab Shows SOC-Comparable Response And Improved Safety Profile In Metastatic Urothelial Cancer Phase 2 Study
In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for
05-22 05:07
Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.73) by 19.18 percent. This is a 1.14 percent increase over losses of $(0.88) per share
04-30 19:25
Bicycle Therapeutics Issues Updates From Its EphA2 Pipeline At The American Association for Cancer Research (AACR) Annual Meeting 2026
AACR Annual Meeting 2026 Data HighlightsNuzefatide pevedotin (nuzefatide), formerly BT5528, a potentially first-in-class EphA2 targeting Bicycle® Drug Conjugate (BDC®), Phase 1/2 data in combination with
04-20 19:11
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12
Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight and lowers the price target from $13 to $12.
04-08 21:29
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15
Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $24 to $15.
03-18 18:00
